Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07HPJ
|
||||
| Former ID |
DCL000364
|
||||
| Drug Name |
AEW-541
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Multiple myeloma [ICD9: 203; ICD10:C90] | Phase 1 | [547863] | ||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Novartis AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C27H29N5O
|
||||
| Canonical SMILES |
C1CN(C1)CC2CC(C2)N3C=C(C4=C3N=CN=C4N)C5=CC(=CC=C5)OCC6=<br />CC=CC=C6
|
||||
| InChI |
1S/C27H29N5O/c28-26-25-24(21-8-4-9-23(14-21)33-17-19-6-2-1-3-7-19)16-32(27(25)30-18-29-26)22-12-20(13-22)15-31-10-5-11-31/h1-4,6-9,14,16,18,20,22H,5,10-13,15,17H2,(H2,28,29,30)
|
||||
| InChIKey |
AECDBHGVIIRMOI-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
16576952, 24744314, 42555091, 77047325, 112378971, 131465113, 134339014, 135727463, 136367859, 139379995, 144116294, 152258839, 160647690, 162011876, 162038075, 162205109, 162858415, 170499974, 172650119, 174006547, 174529200, 180423170, 186013523, 198954966, 224600186, 225848213, 226472254, 227652472, 228146711, 242059881, 242405913, 242591185, 244262877, 249192717, 249565747, 251963183, 252109901, 252214674, 252215928
|
||||
| Target and Pathway | |||||
| Target(s) | Insulin-like growth factor I receptor | Target Info | Inhibitor | [536474], [536624], [536900] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| FoxO signaling pathway | |||||
| Oocyte meiosis | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| AMPK signaling pathway | |||||
| Focal adhesion | |||||
| Adherens junction | |||||
| Signaling pathways regulating pluripotency of stem cells | |||||
| Long-term depression | |||||
| Ovarian steroidogenesis | |||||
| Progesterone-mediated oocyte maturation | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Proteoglycans in cancer | |||||
| Glioma | |||||
| Prostate cancer | |||||
| Melanoma | |||||
| References | |||||
| Ref 536474 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | ||||
| Ref 536624 | FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis. 2008 Jun;29(6):1096-107. Epub 2008 Feb 7. | ||||
| Ref 536900 | Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Int J Oncol. 2008 Nov;33(5):1107-13. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.